Illumina and Myriad Genetics partner for HRD testing in the U.S.

Illumina (ILMN) and Myriad Genetics (MYGN) announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency – HRD – testing in the U.S. Under the agreement, Illumina TruSight Oncology 500 HRD, a research-use-only test, is now available in the US. The expanded partnership also establishes a unique companion diagnostic alliance for the pharmaceutical industry, which will enable more clinical research for gene-based, targeted therapies. The TSO 500 HRD research test aligns Myriad’s MyChoice CDx HRD technology with Illumina’s pan-cancer test, TSO 500. The test was codeveloped with Merck (MRK) and Myriad Genetics. Myriad and Illumina’s initial partnership led to Illumina’s combined HRD and TSO 500 offering launch worldwide-excluding the US and Japan-in June 2022. The product is available to order now and ready to ship in the US.